Biotech News

Vor Bio To Participate in Upcoming September Conferences

Vor Biopharma (VOR)Vor BiopharmaClinical readout

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in the following investor conferences:

Wells Fargo 21st Annual Healthcare Conference

Forum: Fireside Chat and 1x1 Meetings Date: Tuesday, September 8th Presentation Time: 8:00AM ET

Citi’s 2026 Biopharma Back to School Conference

Forum: Fireside Chat and 1x1 Meetings Date: Wednesday, September 9th Presentation Time: 11:20AM ET

Morgan Stanley 24th Annual Global Healthcare Conference

Forum: 1x1 Meetings Date: Monday, September 14th

Baird’s 2026 Global Healthcare Conference

Forum: Presentation and 1x1 Meetings Date: Tuesday, September 15th Presentation Time: 9:05AM ET

Stifel’s 2026 Virtual Immunology and Inflammation Forum

Forum: Presentation and 1x1 Meetings Date: Wednesday, September 23rd Presentation Time: 11:30AM ET

A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com. A replay of the webcast will be available on the Vor website for approximately 30 days following the presentation.

About Vor Bio Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com . Vor Bio routinely posts information that may be important to investors in the “Investors” section of its website. The Company encourages investors to consult that section of its website regularly.

Related news

VORVor Biopharma2026-11-10 13:00 EST

Vor Bio To Participate in 2026 Jefferies Global Healthcare Conference

BMYBMYBristol-Myers Squibb Company2026-11-19 11:59 EST

Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026

BMYBMYBristol-Myers Squibb Company2026-11-18 14:10 EST

Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease

BMEABiomea Fusion2026-11-10 12:00 EST

Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

VORVor Biopharma2026-11-04 21:15 EST

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ERASErasca2026-11-04 13:30 EST

Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

NRIXNurix Therapeutics2026-11-03 21:01 EST

Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272

TEVATeva Pharmaceutical Industries2026-11-02 13:00 EST

Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis

KYMRKymera2026-10-28 20:01 EST

Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026

Vor Biopharma

Autoimmune B-Cell Therapy Company Vor Bio is developing telitacicept for antibody-driven autoimmune diseases. Telitacicept Telitacicept is a recombinant fusion protein that inhibits both BAFF and APRIL, reducing survival signals for autoreactive B cells and plasma cells. Global Phase 3 Programs The UPSTREAM program is evaluating...

Recent company news

Stock data

Close
18.52 USD
Market cap
740.18M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States